Description of the technology platform

A platform focused on antibody humanization      
PX’Monoclonals differentiates from other CROs by its strategy to evaluate, develop and integrate broad antibody “humanization” technologies and approaches through collaborations with other biotech companies or academic laboratories.

The Hu’S-Map programme, approved by the LyonBiopole competitiveness cluster, will especially address molecular humanization of antibody, humanized mice generation, and production of human antibody from immortalized B lymphocytes. These new technologies will be built up and performed as part of anti-infective therapeutic products development programme.

Examples of collaborations developped     

  •  Humanized mice
In a joint effort, PX’Monoclonals and the company Genoway will work on the generation of transgenic mice capable of producing humanized antibodies. This strategy is based on the replacement and/or the insertion of human sequences to humanize the constant or variable parts of antibodies. Those technologies may also be used for antibody « animalization ».

  •  Human Antibodies
The development of fully human monoclonal antibodies will also be targeted in close cooperation with the INSERM. This programme will consist in the selection of seroconverted patients (patients resistant to a specific infection), patient blood collection, isolation of B lymphocytes, cloning by limited dilution, EBV-immortalization and culture of transformed B cells to produce the human monoclonal antibodies.
Alongside the focus on humanization of therapeutics antibodies, the platform will also develop specific technologies related to the antibody production process (immunization, selection of clones, etc), for example: